More US States Take on Eli Lilly in Court Over Proposed Insulin Pricing Settlement + Regeneron's High Dose Eylea Wins FDA Approval

In this episode, Ayesha talked about how three more US states have filed a lawsuit against Eli Lilly over its proposed $13.5 million insulin pricing settlement. The states join six others who have been fighting Eli Lilly in court since 2017, claiming that the company hiked prices of its insulin product Humalog. The states say the $13.5 million settlement offer from Eli Lilly doesn’t come close to the $1 billion worth of claims the company is facing. Hear more about the insulin pricing controversy in this episode.

Ayesha also talked about the FDA approval of Regeneron’s high dose Eylea (HD Eylea) for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Hear about how high dose Eylea offers less frequent dosing regiments, and how it will be facing Roche’s blockbuster eye injection Vabysmo.

Read the full articles here:

More US States Take on Eli Lilly in Court Over Proposed $13.5 Million Insulin Pricing Settlement

Regeneron’s High Dose Eylea Gets FDA Nod for Wet AMD and DME

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured